The results of phase III clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending

Gastroenterology

Volumn 140, Issue 3, 2011, Pages 746-754

  Pawlotsky, Jeanmichel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TELAPREVIR;

AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL RESISTANCE; CONFERENCE PAPER; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRESS SYNDROME; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; GENOTYPE; HEPATITIS C; HUMAN; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; SIDE EFFECT; TREATMENT DURATION;

EID: 79952307519     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.01.028     Document Type: Conference Paper

References (15)

1. F. Poordad, J. McCone, and B.R. Bacon Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-nave patients with hepatitis C virus (HCV) genotype 1: SPRINT-2 final results Hepatology 52 suppl 2010 402A
2. B.R. Bacon, S.C. Gordon, and E. Lawitz HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin Hepatology 52 suppl 2010 430A
3. I.M. Jacobson, J.G. McHutchison, and G.M. Dusheiko Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-nave patients: final results of Phase 3 ADVANCE study Hepatology 52 suppl 2010 427A
4. K.E. Sherman, S.L. Flamm, and N.H. Afdhal Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study Hepatology 52 suppl 2010 401A
5. T.L. Kieffer, D.J. Bartels, and J. Sullivan Clinical virology results from telaprevir Phase 3 study ADVANCE Hepatology 52 suppl 2010 879A
6. P.Y. Kwo, E.J. Lawitz, and J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
7. P. Marcellin, X. Forns, and T. Goeser Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C Gastroenterology 2010 Oct 26 [Epub ahead of print]
8. H. Montaudie, T. Passeron, and N. Cardot-Leccia Drug rash with eosinophilia and systemic symptoms due to telaprevir Dermatology 221 2010 303 305
9. Y. Benhamou, J. Moussali, and V. Ratziu Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients J Hepatol 50 suppl 1 2009 S6
10. G.R. Foster, C. Hezode, and J.P. Bronowicki Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-nave genotype 2 and 3 hepatitis C patients: interim results of study C209 J Hepatol 50 suppl 1 2009 S22
11. C. Hezode, N. Forestier, and G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
12. S. Zeuzem, M.S. Sulkowski, and F. Zoulim Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study Hepatology 52 suppl 2010 436A
13. S. Chevaliez, A. Soulier, and C. Hezode The IL28B genotype is a major determinant in the induction of a virological response by high-dose peginterferon and ribavirin in null-responders to standard-of-care therapy Hepatology 52 suppl 2010 383A
14. A.S. Lok, D.F. Gardiner, and E. Lawitz Combination therapy with BMS-790052 and BMS-650032 alone or with PegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders Hepatology 52 suppl 2010 877A
15. S. Zeuzem, P. Buggisch, and K. Agarwal Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment-nave, genotype 1 HCV subjects Hepatology 52 suppl 2010 400A